Vertex Pharm and Pfizer Are Market Crash-Ready!!
According to the Motley team, these 2 healthcare stocks should be on your radar to strengthen your portfolio.
VERTEX PHARM (VRTX) – VRTX is the leader in the treatment market for cystic fibrosis (CF). Its latest blockbuster, Trikafta has the potential to help 90% of CF patients. Its global leadership in the CF market is set to last until at least the late 2030s, so the revenue picture looks bright. Beyond CF, Vertex and partner CRISPR THERAPEUT (CRSP) are testing their gene-editing treatment for blood disorders in a pivotal trial. The companies aim to file for approval by the end of the year and could be a game changer since it's a one-time curative treatment. It closed at USD258.650 last Friday.
PFIZER INC (PFE) - Thanks to its coronavirus vaccine, PFE has become a household name. The enormous gains generated from its coronavirus program allows them to invest in the future. One recent investment that could be promising is the purchase of Biohaven Pharmaceutical Holding. This gives PFE Biohaven's commercialized migraine treatment, Nurtec ODT -- and a migraine candidate in nasal spray form that's currently under regulatory review. It closed at USD52.470 last Friday.
In other news, trade to win shares like META, APPLE and more in our RakuTrade & Win contest*.
Trade U.S. Markets from 9:30pm to 4:00am (Malaysia time) at super low brokerage rates of USD 1.70 to USD 24.40 (RM 7 – RM 100).
